Venture Capital Resilient For MedTech Even As Public Markets Wilt – Report
This article was originally published in The Gray Sheet
Executive Summary
The U.S. medical technology industry's access to private venture capital remained largely intact in the first half of 2008, despite a global credit crunch that has depressed public equity financing in the sector, according to a 1report by consulting firm Ernst & Young
You may also be interested in...
Venture Capital For MedTech “Somewhat Resilient,” With 18% Drop In ’08
The U.S. medical technology industry's access to private venture capital remained relatively strong in 2008, while its ability to raise funds through debt and public stock offerings took a beating from the global financial crisis, according to a recent 1report by consulting firm Ernst & Young
Venture Capital For MedTech “Somewhat Resilient,” With 18% Drop In ’08
The U.S. medical technology industry's access to private venture capital remained relatively strong in 2008, while its ability to raise funds through debt and public stock offerings took a beating from the global financial crisis, according to a recent 1report by consulting firm Ernst & Young
CSI Takes Reverse Merger Route To Public Market As IPO Options Fade
Atherectomy catheter device maker Cardiovascular Systems Inc. will merge with antibiotic drug developer Replidyne for access to the biopharma firm's cash and public shell under a Nov. 4 stock-swap agreement